Fenofibric Acid
NDC Package 68134-602-30
Package Information
Fenofibric Acid is tablets are contraindicated in:patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.3)].patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)].patients with known hypersensitivity to fenofibric acid or fenofibrate [see Warnings and Precautions (5.9)].nursing mothers [see Use in Specific Populations (8.2)]. Marketed by Palmetto Pharmaceuticals, Inc, this product is identified by NDC 68134-602 and is authorized under FDA application NDA022418.
Identification & Billing
- RxCUI: 860880 - fenofibric acid 105 MG Oral Tablet
- RxCUI: 860886 - fenofibric acid 35 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68134 - Palmetto Pharmaceuticals, Inc
- 68134-602 - Fenofibric Acid
- 68134-602-30 - 30 TABLET in 1 BOTTLE, PLASTIC
- 68134-602 - Fenofibric Acid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68134-602-30 identifies a specific commercial package of 30 tablet in 1 bottle, plastic of Fenofibric Acid, labeled by Palmetto Pharmaceuticals, Inc. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Palmetto Pharmaceuticals, Inc on October 07, 2020. The current certification is valid through December 31, 2022.
How is this Palmetto Pharmaceuticals, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68134060230. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.